Publications by authors named "Diletta Barone"
Background: In advanced pancreatic ductal adenocarcinoma (PDAC), first-line chemotherapy is the standard of care. Due to the absence of head-to-head comparisons in clinical trials, we performed this systematic review and network meta-analysis to compare treatment options for PDAC in terms of their efficacy and toxicity.
Methods: PubMed, the Cochrane Central Register of Controlled Trials, Embase, and oncological meetings websites were searched until Nov 15, 2023.
Article Synopsis
- * Researchers compared hormone levels among three groups: male patients with ALK-positive ANSCLC (cohort A), female patients with ALK-positive ANSCLC (cohort B), and male patients with ALK-negative ANSCLC (cohort C).
- * Results indicated that male patients in cohort A had significantly lower testosterone and higher follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels compared to cohort C, suggesting that androgen deficiency symptoms should
Article Synopsis
- In patients with extensive-stage small cell lung cancer (ES-SCLC) receiving maintenance immunotherapy (IT), higher levels of the adipokine leptin and a favorable leptin-to-visceral fat ratio were linked to improved progression-free survival (PFS).
- A study using blood samples and CT scans found that clusters of patients with high leptin and low pro-inflammatory markers had better outcomes, with significantly longer PFS and overall survival (OS) compared to others.
- The findings suggest that adipokines may influence the effectiveness of immunotherapy in cancer treatment, indicating a need for further research on metabolic immune dysfunctions in a larger patient cohort.
Article Synopsis
- The role of Aurora kinases (AURKs) in cell cycle regulation is significant, as their hyperexpression contributes to cancer progression and drug resistance in both NSCLC and SCLC.
- This review aims to examine the evidence surrounding AURK inhibitors in lung cancer, encompassing studies from preclinical phases to ongoing clinical trials.
Background: Necuparanib, a rationally engineered low-molecular-weight heparin, combined with gemcitabine/nab-paclitaxel showed an encouraging safety and oncologic signal in a phase Ib trial. This randomised multicentre phase II trial evaluates the addition of necuparanib or placebo to gemcitabine/nab-paclitaxel in untreated metastatic pancreatic ductal adenocarcinoma (PDAC).
Patients And Methods: Eligibility included 18 years, histologically or cytologically confirmed metastatic PDAC, measurable disease and Eastern Co-Operative Oncology Group performance status of 0-1.
Background: Current treatment for metastatic pancreatic ductal adenocarcinoma includes combination chemotherapy, such as FOLFIRINOX or nab-paclitaxel plus gemcitabine. We investigated the activity of a novel four-drug regimen, consisting of cisplatin, nab-paclitaxel, capecitabine, and gemcitabine, compared with nab-paclitaxel plus gemcitabine, in the PACT-19 trial.
Methods: This single-centre, randomised, open-label, phase 2 trial was done in San Raffaele Hospital in Italy.